2018Research into comorbidity has expanded exponentially in recent years, with over 55,000 papers published in the medical literature over the past seven years, according to a new analysis of the Web of Science database of biomedical publications (Catala-Lopez et al. PLoS One 2018;13:e0189091). The literature search terms included “comorbidity”, in which there is another medical condition in addition to an index disease; as well as the emerging “multimorbidity”, a more patient-centric term in which no index disease is defined and all conditions are viewed with equal importance. Several neologisms have been coined less successfully, such as “multipathology”, “polymorbidity”, “polipathology”, and “pluripathology”. Read More
Latest News
ECTRIMS/EAN publish new MS treatment guidelines
January 30, 2018The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published new guidelines on the use of disease-modifying drugs (DMDs) for multiple sclerosis (Montalban et al. Mult Scler 2018; epublished January 1, 2018; free full text at http://journals.sagepub.com/doi/pdf/10.1177/1352458517751049). The groups identified 10 key questions, and issued a series of recommendations based on the level of evidence.
The following is a summary of the groups’ recommendations. Read More
2017 U.S. drug approvals in neurology and psychiatry
January 19, 2018The U.S. Food and Drug Administration approved 46 new therapies in 2017, up from only 22 the year before. The following is a list of the new medications for neurology and psychiatry. Read More
Long-term efficacy, safety of DMTs in MS
December 20, 2017SPECIAL REPORT
7TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017
Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab Read More